Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/g9etm185

THE INFLUENCE OF GENOMICS ON PERSONALIZED MEDICINE AND PUBLIC HEALTH POLICIES

Dr Ashwini L H[1*], Dr Vinaykumar L H[2], Dr Hanumanaik L[3]

[1*]Ex-Assistant Professor, JJM Medical College and rc Davanagere, Karnataka
[2]Administrative Medical Officer Phc Aladageri Hirekerur tq, Haveri District
[3]Chief Medical Officer GH Harihara, Harihara tq, Davanagere District

***Corresponding Author:** Dr Ashwini L H
*Ex-Assistant Professor, JJM Medical College and rc Davanagere, Karnataka

Abstract
With genomics, precise healthcare interventions resulting from genetic profiles enable revolutionizing personalized medicine as well as public health policy. This study explores how genomic data can affect healthcare by examining the associations between genetic variants and major health conditions such as cardiovascular disease, type 2 diabetes, and lung cancer. Using a mixed methods approach, the study combines a systematic review of existing literature, analysis of data from reputable genomic databases, and case studies to ground genomics in healthcare. Population Specific Genetic Markers were identified using Genome Wide Association Studies (GWAS) and Polygenic Risk Scores (PRS) and significant associations were found that highlight the predictive power of genomics in the prevention and treatment of disease. Results show that increased likelihood of policy adoption is associated with high PRS values, implying that genomic insights can be used to target public health interventions. Specifically, ethical considerations of data privacy, patient consent and equitable access were considered as genomics was integrated into public health methods, with the call to integrate responsibly. The present study provides novel insights by linking PRS to the adoption of public health policy and demonstrating the potential for genomics to facilitate both personalized healthcare and equitable public health policy. Future research should be directed to expanding genetic databases regarding populations which can be underrepresented and refining algorithms that incorporate lifestyle factors to improve predictive accuracy.

Keywords: personalized medicine, public health policy, Genome-Wide Association Studies, Polygenic Risk Scores, genetic data,data privacy

Introduction

In the past few years genomic science has profoundly transformed the field of personalized medicine, making the promise of providing individualized healthcare approaches based on genetic, environmental, and lifestyle differences. Genetic variations become manifested in disease susceptibility, drug response and treatment efficacy through the newly emerged genomics pathways (Bauer et al., 2014). Researchers and clinicians now can map genetic information to provide targeted therapeutic interventions that ultimately improve treatment outcomes. The shift from traditional ‘one-size-fits-all’ treatment to individualized healthcare has significant implications for both clinical practices and patient outcomes (Prasher et al., 20216). Additionally, genomics

prospects integrate into routine medical care for early disease detection and prevention, reducing sociocultural and economic burden of the chronic diseases (Franzago et al., 2020).

Genomics reaches beyond the individual patient to the public health policy at the systemic level. This provides genomic insights to support policymakers to develop strategies to mitigate the spread of those diseases through disease prevention, outbreak management, and population health monitoring (Burke et al., 2010). For example, public health initiatives can be targeted, for instance, toward population specific genetic risk factors and then screened (i.e., genetic predispositions to conditions) or be targeted to vaccination campaigns (Burke, et al., 2006). Genomic data may also be useful to allocate resources efficiently, by focusing on high-risk groups, improving healthcare equity and spending public finances wisely (Galasso, 2019). In this paradigm shift, the emphasis is on regulatory frameworks that protect patient privacy online while at the same time enabling ethical use of genomic data in public health application (Farmer & Goudard, 2011).

The goal of this study is to explore how genomics will impact personalized medicine and what implications that will have for public health policy. Specifically, it seeks to assess the current integration of genomic data into personalized healthcare practices; to investigate the impact of genomics on public health policy formulation; and to identify key challenges and opportunities for using genomics in public health. This research adds to an emerging literature on how genomic advances can improve healthcare delivery and inform policy decisions by exploring these dimensions.

Methodology

Study Design and Approach

By employing a mixed methods approach, combining quantitative and qualitative data, this study analyzes the effect of genomics on personalised medicine and public health policies. It consists of a systematic review of genomic literature, genomic database data analysis and case studies to provide context for the use of genomics in personalized healthcare and public health decision making. Using this approach, statistical patterns and policy implications were understood in a nuanced way (Creswell & Plano Clark, 2017).

Data Collection and Genomic Data Sources

Reputable genomic databases such as the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO), the European Genome-phenome Archive (EGA) and the Genome Aggregation Database (gnomAD) were used to obtain secondary data. Extensive datasets of genetic variation and phenotypic associations were provided by these sources for conditions that are commonly addressed in public health policies, including cardiovascular disease, type 2 diabetes, and lung cancer. The data collection is on publicly available open access datasets to ensure ethical standards and transparency and reproducibility.

Inclusion and Exclusion Criteria

Adults aged 18 years or older with documented health conditions of interest, such as cardiovascular disease, type 2 diabetes, or lung cancer, and complete genomic datasets including demographic details, polygenic risk scores (PRS) and genetic variant information, were included in the study. To reduce confounding factors and improve specificity, individuals with incomplete genomic or health data, as well as those with rare genetic conditions or significant comorbidities affecting primary health conditions, were excluded.

Sample Collection and Sample Size

For this study, a sample of approximately 1,000 participants was selected from the genomic databases that were used, to be sure to represent as many ages, genders and ethnicities as possible to make the study more generalizable. Python scripts were used to extract and standardize data from multiple sources to minimize the variability that may impact our analysis outcomes. In this research, the data used was secondary data analysis and hence informed consent had been obtained earlier by

the original researchers with the participants consenting to the use of their anonymized data for research. According to ethical and privacy regulations, no personal identifiable information was accessed.

Analytical Techniques

The study uses several analytical techniques to examine the influence of genomics in personalized medicine and public health.

1. **Genome-Wide Association Studies (GWAS):** Genetic variants were correlated to specific health outcomes in GWAS. Associations were assessed by chi-square test for independence, results expressed as odds ratios (ORs) and 95% confidence intervals (CIs). For this analysis, the formula for calculating ORs is:

$$\text{OR} = \frac{(a \times d)}{(b \times c)}$$

where:

- a and b are the counts of cases and controls with the variant,
- c and d are the counts of cases and controls without the variant.

2. **Polygenic Risk Scores (PRS):** PRS was calculated to estimate individual genetic risk scores for selected diseases. The PRS was calculated as the weighted sum of associated risk alleles:

$$\text{PRS} = \sum_{i=1}^{n} \left(\beta_i \times \text{ genotype }_i\right)$$

where:

- β_i is the effect size for each variant i,
- genotype $_i$ is the individual's genotype for variant i.

This model is crucial for understanding how genetic predispositions contribute to disease risk, aiding personalized medical interventions.

3. **Cluster Analysis for Population-Specific Genomic Data:** Population specific genomic data was subjected to a hierarchical cluster analysis to identify patterns of subgroup genomic variations. Euclidean distance was used as the similarity measure for clustering, calculated as follows:

$$d(x, y) = \sqrt{\sum_{i=1}^{n} (x_i - y_i)^2}$$

where x and y represent the genetic data points being compared. This method identifies population specific genomic traits that can inform targeted public health interventions.

4. **Regression Analysis for Policy Impact Estimation:** Logistic regression models were used to understand the impact of genomics on public health policies. Genetic risk scores and demographic factors were independent variables, while policy implementation status was the dependent variable. The logistic regression formula used was:

$$\text{logit}\,(P) = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \cdots + \beta_n X_n$$

where P is the probability of policy adoption, and $X_1, X_2, \ldots, X_n$ are independent variables representing genomic factors.

Ethical Considerations and Data Privacy

During the study, stringent ethical considerations were applied to protect the privacy and integrity of genomic data. Data access and analysis was done after obtaining ethical clearance from the Institutional Review Board (IRB). All datasets used in this study contain no direct identifiers connecting to individual participants. The data was controlled such that only authorized personnel had access to the data and encrypted systems were used to protect data in storage and analysis.

To conform to the Health Insurance Portability Act (HIPAA) and the General Data Protection Regulation (GDPR), handling data procedures were designed to prevent unauthorized access to patient data as well as protect against the disclosure. The study follows FAIR (Findable, Accessible, Interoperable and Reusable) principles, to make the findings available to the scientific community in line with data security and ethical standards (Wilkinson et al., 2016).

Results

Genomic Data Insights

Genomics' potential for predictive healthcare was shown by Genome Wide Association Studies (GWAS) conducted in this study, which identified significant associations between genetic variants and specific health conditions. These associations are summarized in Table 1, which lists variant IDs, risk alleles, associated health conditions, odds ratios (OR), 95% confidence intervals (CI) and p-values.

Variant ID	Risk Allele	Health Condition	OR	95% CI	p-value
rs10911021	G	Cardiovascular Disease	1.8	1.4 – 2.2	<0.001
rs7903146	T	Type 2 Diabetes	1.5	1.2 – 1.9	<0.001
rs16969968	A	Lung Cancer	2.0	1.6 – 2.5	0.001

The variant rs10911021 with risk allele "G" has been associated with an increased risk of cardiovascular disease, with an OR of 1.8 (95% CI: 1.4 – 2.2) and a statistically significant p-value of <0.001, suggesting individuals with this allele are 80% more likely to develop cardiovascular disease. Another significant variant, rs7903146 in the TCF7L2 gene, has been linked to type 2 diabetes with risk allele "T," showing an OR of 1.5 (95% CI: 1.2 – 1.9) and a p-value of <0.001, indicating a strong association with impaired insulin secretion and glucose metabolism. Additionally, rs16969968, associated with the CHRNA5 gene and lung cancer risk, has a risk allele "A" with an OR of 2.0 (95% CI: 1.6 – 2.5) and a p-value of 0.001, particularly among smokers due to its role in nicotine dependence and cellular response to tobacco carcinogens. These associations reflect the utility of genomic data in enhancing the prediction of disease risk as well as in driving targeted healthcare interventions.

The distribution of Polygenic Risk Scores (PRS) for cardiovascular disease across different age groups is shown in Figure 1.The age and PRS values are significantly positively correlated ($r=0.62$, $p<0.01$), indicating that PRS values increase with age, consistent with the hypothesis of accumulating genetic risk with time.



Figure 1: Distribution of PRS for Cardiovascular Disease by Age Group

Population-Specific Genomic Patterns

Population-specific genomic data were hierarchically clustered to reveal patterns of subgroup variability, showing significant genetic differences. Bar graph of these clusters is shown in figure 2 with key clusters highlighted. Within clusters, statistical testing confirmed that genetic risk profiles were different (ANOVA, $F=5.67$, $p<0.05$), indicating that some clusters had a greater genetic predisposition to conditions like type 2 diabetes.



Figure 2: Population-Specific Genomic Clusters

Implications for Personalized Medicine

The GWAS and PRS analyses convey treatment strategies of personalized medicine. PRS ranges and predicted responses to medications for cardiovascular disease, type 2 diabetes, and lung cancer are presented in Table 2. Logic regression (OR=2.5, $p<0.01$) predicts that individuals with high PRS for cardiovascular disease will respond poorly to Drug A, being 2.5 times more likely to have an adverse response than low PRS patients.

Health Condition	Medication	PRS Range	Predicted Response	Recommendation
Cardiovascular Disease	Drug A	High	Poor	Consider alternative
Type 2 Diabetes	Drug B	Moderate	Moderate	Standard dosage
Lung Cancer	Drug C	Low	Favorable	Proceed as usual

In Figure 3, predicted medication efficacy across PRS ranges for type 2 diabetes is shown in a visual format. PRS values <2.0 were associated with 75% favorable response rate; PRS values >4.0 were associated with a significant drop in efficacy ($p<0.05$).



Figure 3: Predicted Efficacy of Medications Based on PRS for Type 2 Diabetes

Genomic Influence on Public Health Policies

An analysis of logistic regression shows how PRS and population genomic variability contribute to public health policy adoption. Regression coefficients, odds ratios, and significance levels for an increase in cardiovascular PRS show a 1.91 times higher probability of adopting related health policies ($p<0.01$).

Predictor	Coefficient (β)	Odds Ratio (Exp(β))	p-value
Cardiovascular PRS	0.65	1.91	<0.01
Type 2 Diabetes PRS	0.45	1.57	0.02
Population Genomic Variability	0.72	2.05	<0.01

The likelihood of adoption of policy based on PRS values for major health conditions is illustrated in Figure 4 below and a positive trend is clearly evident. The statistically significant trend line ($p<0.01$) shows that higher PRS scores are associated with greater likelihood of policy adoption.



Figure 4: Likelihood of Policy Adoption Based on PRS for Major Health Conditions

Discussion

This study finds, however, the transformative potential of genomics in driving personalized medicine development and shaping public health policies. Through Genome Wide Association Studies (GWAS), there are significant associations of genetic variants, such as rs10911021 (which is linked with cardiovascular disease), rs7903146 (which is associated with type 2 diabetes), and rs16969968 (which is also linked with lung cancer). However, these associations yield actionable insights into disease susceptibility, and therefore, can enable the realization of predictive potential of genomics in healthcare (Brand, 2012). In addition, the tailoring of healthcare interventions based on demographic factors (Offit, 2011), such as Polygenic Risk Scores (PRS), further strengthens the predictive capacity of first rank risk identification in population specific risk. The hierarchical cluster analysis also reveals genetic patterns among certain population subgroups, indicating that genomic interventions can be targeted to the needs of different communities (Franzago et al., 2020).

This provides genomic insight into highly individualized therapeutic strategies that take account of genetic predisposition to diseases. This study shows that, as illustrated in this use of PRS, use of PRS for evaluating medication efficacy shows that high PRS for cardiovascular disease is associated with a lower response to Drug A and thus suggests alternative therapies (Galasso, 2019). This follows recent research that has focused on genetic profiles as enhancing patient outcomes with tailored therapies (Hall et al., 2004). The results demonstrate that patients with high PRS for type 2 diabetes may need dose adjustment to achieve the best drug efficacy, highlighting the need to incorporate genomic data into clinical decision making. This is the capacity to predict treatment response not only improving patient care but also reducing adverse effects and healthcare costs of ineffective treatments (Geller et al., 2014).

Genomic data should be incorporated as a foundational tool for preventive healthcare in public health policies to fully harness the benefits of genomics. Genomics integration into public health frameworks necessitates creating national genetic registries, developing genomic information responsible use guidelines, and fostering healthcare providers, genetic counselors and policymaker collaborations (Burke et al. 2010). Because population-wide genetic screening could be developed for high-risk groups, governments could develop policies that would encourage such screening to allow for early diagnosis and prevention. In addition, investing in genomic research infrastructure capacity and workforce training, as well as public awareness, will help ensure that ethnic minorities' genomic data are ethically managed and the results are applied towards enhancing healthcare equity for diverse populations (Khoury et al., 2018).

It is thus possible to best implement personalized medicine by combining Polygenic Risk Scores (PRS) and Genome Wide Association Studies (GWAS) data into patient care (Galasso, 2019). Genetic data should be interpreted by health care providers and used in creating individual treatment plans. Adding partnerships with pharmaceutical companies, as well as frameworks for insurance coverage of genomic testing can lead to making personalized medicine more available (Quaak et al., 2009). Standardized guidelines for genomic data use in decisions for treatment would improve consistency in patient care and lead to more providers to adopt personalized practice (Offit, 2011; Green, & Patel, 2021).

Preparations for genomics to be more thoroughly integrated into healthcare require policies to put the ethical considerations of patient consent, data anonymity and privacy protections first. Frameworks such as HIPAA and GDPR, in this respect, should mandate strict penalties for noncompliance that governments enforce — genomic data should be stored securely and is only accessible to approved personnel (Farmer and Godard, 2011). Especially in public health databases, genomic data should be processed in ways that include transparency about how the data will be used and stored. Furthermore, public public health policies need to take into cognizance the possibility of disparities in the access to genomic medicine to avert inequality and create equal access to underserved communities.

The implications of the study’s findings are that genomics can help to inform public health policy making in a way that leads to more efficient resource allocation and targeted interventions. For example, policies incorporating use of PRS for cardiovascular disease or type 2 diabetes can direct

early intervention to high-risk populations, and thereby could influence the incidence and severity of these diseases on a population level (Khoury et al., 2018). In addition, logistic regression analysis revealed that a higher PRS was correlated with a higher probability of policy adoption, suggesting that genomic data can support the rationale for public health interventions and resource allocation to at risk communities. This is consistent with other studies that suggest genomics based public health policies can help improve health equity by focusing on the different genomic profiles of different demographics and optimizing public health outcomes (Geller et al., 2014).

The findings of this study are in line with previous research on the important role of genomics in improving the precision of healthcare and public health response. Just as Brand (2012), Ginsburg et al. (2018) have shown the bearing of PRS and GWAS in predicting disease susceptibility and in guiding clinical practice. However, this research extends previous literature by directly associating PRS with the adoption of public health policy, with empirical evidence of genomics informed policy formulation. Furthermore, while the current research has largely focused on patient level outcomes, this work extends the scope by looking at how genomics informs policies that benefit entire populations. The dual emphasis on personalized healthcare and public health policy reflects the increasing value of genomics as a basic tool in the clinic as well as in public health.

Conclusion

This study shows how genomics can greatly improve personalized medicine and inform public health policy. Genetic variants and Polygenic Risk Scores (PRS) can help to inform individualized treatment plans and public health resource allocation. Nevertheless, the findings are limited by reliance on secondary data and the necessity for more varied population datasets in order to generalize results. More extensive genetic databases should be developed including underrepresented populations, and algorithms should be developed to integrate genomic and lifestyle data for better risk prediction, said the researchers. Taken together, the results highlight the relevance of genomics in advancing healthcare, providing a road map for more specific, fairer and more effective medical and public policy interventions.

References

1. Bauer, D. C., Gaff, C., Dinger, M. E., Caramins, M., Buske, F. A., Fenech, M., ... & Cobiac, L. (2014). Genomics and personalised whole-of-life healthcare. *Trends in molecular medicine*, *20*(9), 479-486.
2. Brand, A. (2012). Public health genomics and personalized healthcare: a pipeline from cell to society. *Drug Metabolism and Drug Interactions*, *27*(3), 121-123.
3. Burke, W., Burton, H., Hall, A. E., Karmali, M., Khoury, M. J., Knoppers, B., ... & Zimmern, R. L. (2010). Extending the reach of public health genomics: what should be the agenda for public health in an era of genome-based and "personalized" medicine? *Genetics in Medicine*, *12*(12), 785-791.
4. Burke, W., Khoury, M. J., Stewart, A., & Zimmern, R. L. (2006). The path from genome-based research to population health: development of an international public health genomics network. *Genetics in Medicine*, *8*(7), 451-458.
5. Creswell, J. W., & Clark, V. L. P. (2017). *Designing and conducting mixed methods research*. Sage publications.
6. Farmer, Y., & Godard, B. (2007). Public health genomics (PHG): from scientific considerations to ethical integration. *Genomics, Society and Policy*, *3*(3), 14.
7. Franzago, M., Santurbano, D., Vitacolonna, E., & Stuppia, L. (2020). Genes and diet in the prevention of chronic diseases in future generations. *International journal of molecular sciences*, *21*(7), 2633.
8. Galasso, I. (2019). Precision medicine in society: Promises, expectations and concerns around social and health equity.

9. Geller, G., Dvoskin, R., Thio, C. L., Duggal, P., Lewis, M. H., Bailey, T. C., ... & Kahn, J. P. (2014). Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice. *Genome medicine*, *6*, 1-13.
10. Ginsburg, G. S., & Phillips, K. A. (2018). Precision medicine: from science to value. *Health affairs*, *37*(5), 694-701.
11. Hall, W. D., Morley, K. I., & Lucke, J. C. (2004). The prediction of disease risk in genomic medicine: Scientific prospects and implications for public policy and ethics. EMBO reports, 5(S1), S22-S26.
12. Khoury, M. J., Bowen, M. S., Clyne, M., Dotson, W. D., Gwinn, M. L., Green, R. F., ... & Yu, W. (2018). From public health genomics to precision public health: a 20-year journey. *Genetics in Medicine*, *20*(6), 574-582.
13. Offit, K. (2011). Personalized medicine: new genomics, old lessons. *Human genetics*, *130*, 3-14.
14. Prasher, B., Gibson, G., & Mukerji, M. (2016). Genomic insights into ayurvedic and western approaches to personalized medicine. *Journal of genetics*, *95*, 209-228.
15. Quaak, M., Van Schayck, C. P., Knaapen, A. M., & Van Schooten, F. J. (2009). Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. *European Respiratory Journal*, *33*(3), 468-480.
16. Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., ... & Mons, B. (2016). The FAIR Guiding Principles for scientific data management and stewardship. *Scientific data*, *3*(1), 1-9.